Ozempic and antibody combination restores liver homeostasis
New study results have demonstrated the anti-inflammatory potential of Tiziana Life Sciences’ anti-CD3 antibody foralumab in combination with semaglutide (Ozempic/Wegovy).
The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO).
In humans, nasal foralumab modulates immune responses by inducing regulatory-type T cells.
The study, conducted by a research team at Brigham and Women’s Hospital, Boston, Massachusetts, demonstrates that nasal anti-CD3 in combination with semaglutide, helps restore liver homeostasis in diet-induced obesity models where liver dysfunction and inflammation are prominent.
The combination therapy led to marked reductions in pro-inflammatory cytokines and significant improvements in liver markers associated with metabolic regulation.
This suggests a dual benefit in both managing obesity and preventing its associated inflammation-related complications.
“We are excited by the potential of this novel combination. Nasal foralumab’s ability to modulate immune response in humans has always been promising. Now, combining anti-CD3 with semaglutide resulted in additional benefit on liver homeostasis and reduced inflammation in this mouse model. This could pave the way for an entirely new approach in treating obesity-related metabolic disorders,” said Dr Howard Weiner, Chairman of Tiziana’s Scientific Advisory Board and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham healthcare system.
Effect observed in Covid-19 and MS patients
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. It is currently being studied in a Phase IIa trial in patients with non-active secondary progressive multiple sclerosis.
Foralumab binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been observed in patients with Covid-19 and with multiple sclerosis, as well as in healthy normal subjects.
Dr Selma Boulenouar, a researcher at Brigham and Women’s Hospital, who co-led the latest study, commented: “The results of this study are very encouraging. Chronic inflammation is a hallmark of obesity and liver diseases. The combination of anti-CD3 with semaglutide appears to mitigate this inflammatory response and restore normal liver function. These findings underscore the potential for combination therapies in addressing complex metabolic and inflammatory conditions.”
Diana Spencer, Senior Digital Content Editor, DDW
